tirzepatide ampoule Flex-Dose 3 mL Injectable 10 mg/mL Lilly releases Zepbound® (tirzepatide) single-dose

If you have a history of disordered eating, depression, or suicidal thoughts, you may need to hold off entirely or be extra careful by making sure you receive psychological support throughout the process

The Phase 2/3 LIFT-AD trial (NCT04488419), evaluating once-daily subcutaneous fosgonimeton 40 mg versus placebo in 312 participants with mild-to-moderate Alzheimers disease over 26 weeks, failed its primary endpoint (Global Statistical Test composite of ADAS-Cog11 and ADCS-ADL23) and its key secondary endpoints when results were announced in September 2024

15 The selected studies were broadly homogeneous in terms of study design

Log consult answers, patient questions, consents, product lot info, all follow-ups, reorder and refill requests, and updates from check-ins